RESEARCH-USE BIOSIMILAR ANTIBODY
Lacutamab
Monoclonal antibody · IgG1
Lacutamab (IPH 4102) is a humanized monoclonal antibody targeting KIR3DL2/CD158k, which eliminates KIR3DL2-expressing cells via antibody-dependent cellular cytotoxicity and phagocytosis. Lacutamab is applicable to research related to mycosis fungoides, relapsed or refractory peripheral T-cell lymphoma, and relapsed or refractory cutaneous T-cell lymphoma.
PRODUCT OVERVIEW
A research-use configuration for comparative antibody studies
Lacutamab (IPH 4102) is a humanized monoclonal antibody targeting KIR3DL2/CD158k, which eliminates KIR3DL2-expressing cells via antibody-dependent cellular cytotoxicity and phagocytosis. Lacutamab is applicable to research related to mycosis fungoides, relapsed or refractory peripheral T-cell lymphoma, and relapsed or refractory cutaneous T-cell lymphoma.
Lacutamab is a recombinant research-use antibody directed against KIR3DL2.